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Abstract
Background: Amyotrophic lateral sclerosis is a neurodegenerative disease of motor neurons resulting in progressive paraly-
sis and death, typically within 3–5 years. Although the heritability of ALS is about 60%, only about 11% is explained by
common gene variants, suggesting that other forms of genetic variation are important. Telomeres maintain DNA integ-
rity during cellular replication and shorten naturally with age. Gender and age are risk factors for ALS and also associ-
ated with telomere length. We therefore investigated telomere length in ALS. Methods: We estimated telomere length by
applying a bioinformatics analysis to whole genome sequence data of leukocyte-derived DNA from people with ALS and
age and gender-matched matched controls in a UK population. We tested the association of telomere length with ALS
and ALS survival. Results: There were 1241 people with ALS and 335 controls. The median age for ALS was 62.5 years
and for controls, 60.1 years, with a male–female ratio of 62:38. Accounting for age and sex, there was a 9% increase of
telomere length in ALS compared to matched controls. Those with longer telomeres had a 16% increase in median sur-
vival. Of nine SNPs associated with telomere length, two were also associated with ALS: rs8105767 near the ZNF208
gene (p¼1.29104) and rs6772228 (p = 0.001), which is in an intron for the PXK gene. Conclusions: Longer telo-
meres in leukocyte-derived DNA are associated with ALS, and with increased survival in those with ALS.
KEYWORDS: ALS; telomere; next-generation sequencing; whole genome sequencing; bioinformatics; variant calling;
structural variants
Introduction
Amyotrophic lateral sclerosis is a neurodegenera-
tive disease of motor neurons leading to progres-
sive muscle weakness and death through
neuromuscular respiratory failure (1). Although
the heritability of ALS is about 60% (2), the herit-
ability explained by common gene variants is only
about 11% (3) suggesting that other forms of gen-
etic variation play an important role.
Telomeres are repeated DNA sequences
located at the ends of chromosomes and exist to
maintain DNA integrity during cellular replication;
chromosome ends tend to shorten with replication,
and the repeat region protects against the loss of
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important gene sequences because loss of repeats
can be tolerated (4). As such, telomeres shorten
naturally with age as repeats are lost during repli-
cation cycles (5). Natural variation in telomere
length exists in the population, with women on
average having longer telomeres than men (6);
shorter telomeres are associated with an increased
risk of cancer (7).
A major risk factor for ALS is age (8) and ALS
is also more common in men than women (9):
both age and sex are related to telomere length.
Furthermore, there are some similarities between
ALS and cancer (10), such as evidence for a multi-
step process in pathogenesis (11,12). We therefore
investigated telomere length in ALS.
Materials and methods
Whole-genome sequencing
Samples were from multiple centers across the UK
contributing to the international Project MinE
whole genome sequencing initiative (13).
DNA was isolated from venous blood using
standard methods. The DNA concentrations were
set at 100 ng/uL as measured by a fluorimeter with
the PicoGreenVR dsDNA (Thermo Scientific,
Waltham, MA) quantitation assay. DNA integrity
was assessed using gel electrophoresis. All samples
were sequenced using Illumina’s FastTrack serv-
ices (Illumina, San Diego, CA) on the Illumina
HiSeq 2000 platform (14). Sequencing was 100bp
paired-end performed using polymerase chain
reaction (PCR)-free library preparations and
yielded 40x coverage across each sample. Binary
sequence alignment/map formats (BAM) were gen-
erated for each individual.
Determination of telomere length
TelSeq (15) was used to quantify telomere length
using data from whole genome sequences.
Telomere lengths were estimated from reads,
defined as repeats of more than seven
TTAGGG motifs.
Assessment of nine loci affecting mean telomere length
and their association with ALS
We selected nine SNPs, reported in multiple
genome-wide association studies (GWAS) as asso-
ciated with mean telomere length in European-
derived populations. The selected SNPs were
rs6772228-PXK (16), rs9419958-OBFC1 (17),
rs9420907-OBFC1 (18), rs4387287- OBFC1
(10), rs3027234-CTC1 (17), rs8105767-ZNF208
(18), rs412658-ZNF676 (17), rs6028466-DHX35
(17), and rs755017-ZBTB46 (17).
Statistical analysis
The effects of telomere length on ALS were tested
using a generalized linear regression model, which
included total telomere length, age and sex, to pre-
dict disease affected status. To assess the model,
Pearson’s chi-squared test was used.
Because telomere length correlates with age, we
performed an additional test to examine the possi-
bility that survival bias could affect the results. To
do this, we also performed the analysis restricted
to the subgroup of people with ALS onset below
the median cohort age (62 years). Although such
an analysis would halve our sample and therefore
greatly reduce statistical power, the direction of
effect should be observable.
To evaluate SNP effects on telomere length we
calculated Nagelkerke’s R2 from the results of a
generalized linear model using the value of telo-
mere length, age, gender, and nine SNPs selected
for having been previously shown to associate with
telomere length.
To assess the effect of covariates on telomere
length affecting survival, we used Cox regression,
controlling for age, gender, and site of disease
onset (bulbar or spinal).
To assess the association of genes with ALS we
used the SNP-set sequence kernel association test
(SKAT) (19), which is a test for association
between a set of rare and common variants and
continuous/dichotomous phenotypes using kernel
machine methods.
Statistical tests were performed using IBM
SPSS Statistics version 24.0 (SPSS Inc., Armonk,
NY, USA) (20), RStudio, R Foundation for
Statistical Computing version 3.4.1 (R
Development Core Team, Vienna, Austria) (21).
Ethical approval
Informed consent was obtained from all volunteers
included in this project. Generation of whole gen-
ome sequences was approved by the Trent
Research Ethics Committee 08/H0405/60.
Results
There were 1241 people with apparently sporadic
ALS and 335 controls. The median age for people
with ALS was 62.5 years and for controls, 60.1
years, with a male–female ratio of 62:38 (Table 1).
Table 1. Demographics of the UK sample.
ALS Controls
Total n 1241 335
Male:Female
ratio
766:475 (62% male) 124:211 (37% male)
Mean age 62.9 (SD 11.08) 60.1 (SD 11.47)
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The mean telomere length in people with ALS
was 3.95 kb, and in controls, 3.80 kb, not taking
into account gender or age (Figure 1). Generalized
linear regression accounting for these covariates
showed a mean 9% (95% CI 3%, 15%) increase
of telomere length in people with ALS compared
to age and gender-matched controls (p¼0.008).
In the analysis exploring survival bias as an explan-
ation for our results, in which we restricted testing
to those younger than the median age, the same
direction of effect was observed, although as
expected, because of the greatly reduced sample
size, this did not reach statistical significance
(p¼0.08). Covariate analysis showed that females
(p¼0.03) and younger people (p¼ 21016) had
on average longer telomeres (Table 2), confirming
the results of earlier studies that telomere length
reduces with age and females have on average lon-
ger telomeres.
There was no association between telomere
length and site of disease onset (p¼ 0.7), or with
C9orf72 expansion status (p¼ 0.24).
Cox regression analysis showed that in the ALS
group, those with longer telomeres had a 16%
increase in median survival (hazard ratio 0.81
(95% CI 0.72–0.91), p¼ 0.001).
The generalized linear regression model showed
that of the nine SNPs associated with telomere
length, two were also associated with ALS:
rs8105767 near the ZNF208 gene (p¼1.29 104,
MAF = 0.03) and rs6772228, which is in an
intron for the PXK gene (p¼0.001, MAF = 0.03;
Table 3), but the SKAT test did not show an associ-
ation of overall variant burden in these genes with
ALS after correction for multiple testing (ZNF208,
p¼ 0.81 and PXK, p¼ 0.03). Nagelkerke’s R2 test
showed that the nine selected SNPs contributed 3%
to the variance in total telomere length.
Discussion
We have shown that longer telomeres are associ-
ated with ALS and with longer survival in ALS. In
keeping with previous studies, we found that mean
telomere length was longer in females and short-
ened with increasing age. Of a panel of nine SNPs
known to be associated with telomere length, two
showed association with ALS, one in ZNF208, and
the other in PXK.
Although both these SNPs, rs6772228 and
rs8105767, are known to be associated with telo-
mere length, no association with ALS was seen in
a previous large genome-wide association study
(22), suggesting that either there is a population-
specific effect, or that the telomere length itself is
driving the association, and other factors that
influence it have a larger effect than these SNPs.
Another possibility is that the difference in results
is because the analysis performed was different, as
we have tested genotypic association, whereas the
genome-wide association study used linear mixed
modeling of alleles.
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Figure 1.. Mean telomere length by age (A), sex (B), and disease status (C). Red bars indicate 95% confidence intervals.
Table 2. Telomere length comparison between people with
ALS and healthy controls using a generalized linear model.
Estimate
(%)
SE of
estimate (%) p Value
Age (per year) 1 0.1 21016
Gender (male vs. female) 5 2 0.03
Case-control status
(controls vs. cases)
9 3 0.008
Telomere length is greater in ALS than in controls 3
Telomeres have largely been investigated for
their roles in cancer and aging, shorter telomeres
being associated with disease pathology and death.
Surprisingly, telomere elongation is also seen in
about 15% of cancers, such as adenocarcinoma of
the lung and pancreas (23), and in general, cancers
with long telomeres are resistant to therapy and
carry a poor prognosis (24). Telomere elongation
phenomena are well documented but far less well
understood than telomere shortening phenom-
ena (24–28).
A study of telomere length in ALS brains found
a trend to longer telomeres in glial cells (29) con-
sistent with our results, but is in contrast to an
earlier small study of 50 people with ALS and 50
controls, finding that shorter telomeres are associ-
ated with ALS (30).
Our study has some strengths and weaknesses.
Although ALS is a disease of the central nervous
system, our telomere data are derived from leuko-
cyte DNA, since our DNA source was whole
blood. The relationship between leukocyte telo-
meres, which can be expected to shorten with age
as leukocytes undergo mitosis, and telomeres in
neurons, which are post-mitotic, is not clear (31),
but glial and other cells that do undergo mitosis
are probably involved in ALS pathogenesis, and
provide a possible mechanism. Furthermore, we
did not directly measure telomere length using
Southern blotting, but estimated it using whole
genome sequence data. However, our findings
have the advantage of a large sample size of more
than 1200 cases, compared with previous reports
of 50 or fewer. Furthermore, our examined cohort
is more homogeneous in genetic background, and
the sequencing technology used was the same
across the entire cohort. However, one limitation
of our method is that we cannot draw firm conclu-
sions about the exact length of a telomere. The
method we have used, TelSeq, correlates with
results from Southern blotting (32), and Q-PCR
(33) and is in widespread use (31,34).
Nevertheless, different sequencing technologies
will generate different telomere length estimates
because of differences in library preparation and
platform (35,36). To overcome this potential
weakness, we have used the same industry-leading
sequencing platform for all samples, as well as
designing the study to minimize batch effects by
having cases and controls sharing the same
sequencing plate.
We found that longer telomeres were associated
both with ALS and with increased survival in
ALS. It is possible that telomere length does not
associate with ALS risk but only with survival, and
that our cohort was biased in such a way that
those with longer survival were more likely to be
genotyped. In that case, we would also observe an
apparent association with risk, but the driver
would be the actual association with increased sur-
vival. While this possibility cannot be completely
excluded, the cohort tested was an incident cohort,
collected from a population rather than a specialist
clinic, reducing the likelihood of this explanation.
Furthermore, we assessed survival bias by testing
the relationship between telomere length and ALS
in the younger half of the sample. We found the
direction of association of longer telomeres with
ALS was still present, although as expected,
the statistical power was reduced due to the smaller
number of young controls (<175). Replicating these
findings in a bigger cohort such as the entire
Project MinE sample is an important future step.
There are multiple methods available for telo-
mere length analysis, including terminal restriction
fragmentation, quantitative fluorescence in situ
Hybridization (Q-FISH) (37), PCR-based techni-
ques and southern blotting. These techniques
have the disadvantage of lengthy protocols and
limitations, such as the requirement that DNA is
extracted from fresh blood, or that chromosomes
are individually stained, which is a time-consum-
ing process (35,38–41). Differences in applying
these techniques between laboratories can create
measurement differences (41). Thus, for large
scale analyses, whole genome sequence data that
can be processed using a standard bioinformatics
pipeline can standardize measurements and over-
come many of these issues (42). We have shown
that measuring telomere length in a UK cohort is
feasible using a bioinformatics tool, such as
TelSeq, and that this is fast and cost-effective.
Estimating the telomere length with TelSeq on a
single 40x whole genome sequence takes about
Table 3. Assessment of telomere-associated SNPs.
SNP Risk genotype Beta SE p Value
rs6772228 A/T 0.83 0.37 0.001
rs6772228 A/A 0.33 0.37 0.001
rs9419958 T/T 0.61 0.56 0.036
rs9419958 C/T 0.59 0.54 0.031
rs9420907 C/C 0.59 0.53 0.021
rs9420907 A/A 0.6 0.53 0.024
rs4387287 A/A 0.71 0.16 0.014
rs4387287 A/C 0.63 0.07 0.067
rs3027234 G/G 0.62 0.07 0.009
rs3027234 A/G 0.63 0.07 0.011
rs8105767 G/A 0.66 0.08 1.293 1024
rs8105767 G/G 0.91 0.07 4.893 1024
rs412658 C/C 0.73 0.07 0.008
rs412658 C/T 0.69 0.06 0.058
rs6028466 G/G 0.36 0.22 0.087
rs6028466 A/G 0.37 0.22 0.088
rs755017 A/A 0.45 0.63 0.054
rs755017 A/G 0.45 0.63 0.052
Investigation of causal effect of telomere length on ALS by
using nine SNPs identified by telomere length GWAS. SNPs
rs8105767 (PXK) and rs6772228 (ZNF208) were associated
with ALS.
SNPs highlighted in bold show association with ALS.
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90min using four threads on a midrange com-
puter, which would translate to about 100 days
for our entire dataset. Since high-performance
computing access is now straightforward, and
multiple computers are able to run the same ana-
lysis in parallel, the analysis time can easily be
shortened significantly.
In this large study of telomere length and ALS,
we have shown that longer telomeres in leukocytes
are associated with ALS, and with increased sur-
vival in those with ALS.
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